Novel cancer therapies targeting key cancer pathways
We are a clinical stage oncology company developing novel drugs
that show great promise as potential new therapies to treat a range of cancers.
OUR COMPANY
Prescient Therapeutics’ novel compounds inhibit key tumor survival pathways, inhibiting cancer growth and overcoming resistance to prior therapies.
OUR SCIENCE
Our technologies emanate from renowned institutions Yale University and the Moffitt Cancer Center and are backed by a myriad of peer review publications.
LATEST NEWS
| 24/09/2018 | Canadian Patent Granted for PTX-200 | |
| 05/09/2018 | Rodman & Renshaw Global Investment Conference Presentation | |
| 04/09/2019 | PTX to present at Rodman & Renshaw Investment conference | |
| 03/09/2018 | Improved manufacturing route for PTX-100 | |
| 31/08/2018 | Appendix 4G and Corporate Governance Statement | |
| 31/08/2018 | Appendix 4E and 2018 Annual Report |